

AUTHOR INDEX FOR VOLUME 38

A

- Adams, M. E., *see* Scott, R. H., 711
 Adham, N., *see* Branchek, T., 604
 Adham, N., *see* Weinshank, R. L., 681
 Agranoff, B. W., *see* Fisher, S. K., 54
 Aicher, L. D., *see* Woods, J. S., 253, 261
 Allegra, C. J., *see* Chu, E., 410
 Allsup, D. J., and Boarder, M. R. Comparison of P₂ purinergic receptors of aortic endothelial cells with those of adrenal medulla: Evidence for heterogeneity of receptor subtype and of inositol phosphate response, 84
 Amblard, M., *see* Rodriguez, M., 333
 Anders, M. W., *see* Vamvakas, S., 455
 Anderson, W. R., *see* Trudell, J. R., 587
 Annunziato, L., *see* Tagliatela, M., 385, 393
 Ardies, C. M., *see* Trudell, J. R., 587
 Arnaudeau, S., *see* Martin, C., 667
 Ashby, B. Novel mechanism of heterologous desensitization of adenylyl cyclase: Prostaglandins bind with different affinities to both stimulatory and inhibitory receptors on platelets, 46
 Åström, A., *see* Craig, P. I., 313
 Atchison, W. D., *see* Shafer, T. J., 102
 Audhya, T., *see* Lukas, R. J., 887

B

- Backes, W. L., *see* Causey, K. M., 134
 Baez, M., Yu, L., and Cohen, M. L. Pharmacological and molecular evidence that the contractile response to serotonin in rat stomach fundus is not mediated by activation of the 5-hydroxytryptamine_{1C} receptor, 31
 Baker, R. M., *see* Rauscher, F. J., III, 198
 Baldessarini, R. J., *see* Booth, R. G., 92
 Ballatori, N., and Truong, A. T. Cholestasis, altered junctional permeability, and inverse changes in sinusoidal and biliary glutathione release by vasopressin and epinephrine, 64
 Baron, B. M., and Siegel, B. W. p-[¹²⁵I]iodoclonidine, a novel radiolabeled agonist for studying central α_2 -adrenergic receptors, 348
 Baron, B. M., Harrison, B. L., Miller, F. P., McDonald, I. A., Salituro, F. G., Schmidt, C. J., Sorensen, S. M., White, H. S., and Palfreyman, M. G. Activity of 5,7-dichlorokynurenic acid, a potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site, 554
 Barrett, R. W., *see* Klueppelberg, U. G., 159
 Barrington, W. W., Jacobson, K. A., and Stiles, G. L. Glycoprotein nature of the A₂-adenosine receptor binding subunit, 177
 Barton, A. C., and Sibley, D. R. Agonist-induced desensitization of D₁-dopamine receptors linked to adenylyl cyclase activity in cultured NS20Y neuroblastoma cells, 531
 Batist, G., *see* Skalski, V., 299
 Bauce, L., *see* Weiss, S., 229
 Bawden, M. J., *see* Srivastava, G., 486
 Beavo, J., *see* Watson, E. L., 547
 Beerman, T. A., *see* Rauscher, F. J., III, 198
 Beilharz, W., *see* Dilollo, D. L., 451
 Bendele, A. M., *see* Lindstrom, T. D., 829
 Benishin, C. G. Potassium channel blockade by the B subunit of β -bungarotoxin, 164
 Bérézat, G., *see* Kadiri, C., 418
 Beumeyer, J. L., *see* Booth, R. G., 92
 Bindokas, V. P., *see* Scott, R. H., 711
 Bleakman, D., Thayer, S. A., Glaum, S. R., and Miller, R. J. Bradykinin-induced modulation of calcium signals in rat dorsal root ganglion neurons *in vitro*, 785
 Boarder, M. R., *see* Allsup, D. J., 84
 Bonhaus, D. W., *see* Yeh, G.-C., 14
 Bonner, T. I., *see* Wess, J., 517, 872
 Booth, R. G., Baldessarini, R. J., Kula, N. S., Gao, Y., Zong, R., and Neumeyer, J. L. Presynaptic inhibition of dopamine synthesis in rat striatal tissue by enantiomeric mono- and dihydroxyaporphines, 92
 Bornheim, L., and Correia, M. A. Selective inactivation of mouse liver cytochrome P-450III_A by cannabidiol, 319
 Bottlaender, M., *see* Brouillet, E., 445
 Boulanger, C., *see* Resnik, T. J., 244
 Boulay, G., *see* Guillemette, G., 841
 Bousli, M., *see* Bueb, J.-L., 816
 Boutjdir, M., Méry, P.-F., Hanf, R., Shrier, A., and Fischmeister, R. High affinity forskolin inhibition of L-type Ca²⁺ currents in cardiac cells, 758
 Bowen, J. A., *see* Goldman, M. E., 20
 Bradford, B. U., *see* Knecht, K. T., 26
 Branchek, T., Adham, N., Macchi, M., Kao, H.-T., and Hartig, P. R. [³H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine and [³H]-ketanserin label two affinity states of the cloned human 5-hydroxytryptamine₂ receptor, 604
 Branchek, T. A., *see* Weinshank, R. L., 681
 Brann, M. R., *see* Wess, J., 517, 872
 Breittmayer, J.-P., *see* Frelin, C., 904
 Brian, W. R., *see* Wrighton, S. A., 207
 Bronner, C., *see* Bueb, J.-L., 816
 Brouillet, E., Chavoix, C., Khalili-Varasteh, M., Bottlaender, M., Hantraye, P., Yorke, J.-C., and Maziere, M. Quantitative evaluation of benzodiazepine receptors in live *Papio papio* baboons using positron emission tomography, 445
 Browning, M. D., *see* Leidenheimer, N. J., 823
 Bruns, R. F., and Fergus, J. H. Allosteric enhancement of adenosine A₁ receptor binding and function by 2-amino-3-benzoylthiophenes, 939
 Bruns, R. F., Fergus, J. H., Coughenour, L. L., Courtland, G. G., Pugaley, T. A., Dodd, J. H., Tinney, F. J. Structure-activity relationships for enhancement of adenosine A₁ receptor binding by 2-amino-3-benzoylthiophenes, 950
 Bruns, R. F., *see* Dudley, D. T., 370
 Buckley, N. J., *see* Lazareno, S., 805
 Budzik, G. P., *see* Von Geldern, T. W., 771
 Bueb, J.-L., Bousli, M., Bronner, C., Rouot, B., and Landry, Y. Activation of G_i-like proteins, a receptor-independent effect of kinins in mast cells, 816
 Bühler, F. R., *see* Resnik, T. J., 244
 Bushfield, M., Shoshani, I., and Johnson, R. A. Tissue levels, source, and regulation of 3'-AMP: An intracellular inhibitor of adenylyl cyclases, 848

C

- Calas, C. A., *see* Woods, J. S., 253, 261
 Campbell, M. D., Subramaniam, S., Kotlikoff, M. I., Williamson, J. R., and Fluharty, S. J. Cyclic AMP inhibits inositol polyphosphate production and calcium mobilization in neuroblastoma x glioma NG108-15, 282
 Camus, J., *see* Waelbroeck, M., 267
 Candell, L. M., Yun, S. H., Tran, L. L. P., and Ehler, F. J. Differential coupling of subtypes of the muscarinic receptor to adenylyl cyclase and phosphoinositide hydrolysis in the longitudinal muscle of the rat ileum, 689

- Canzoniero, L. M. T., *see* Taglialatela, M., 393
 Capranico, G., *see* Wassermann, K., 38
 Caron, M. G., *see* Lorenz, W., 599
 Cashman, J. R., and Olsen, L. D. Stereoselective *S*-oxygenation of 2-aryl-1,3-dithiolanes by the flavin-containing and cytochrome P-450 monooxygenases, 573
 Causey, K. M., Eyer, C. S., and Backes, W. L. Dual role of phospholipid in the reconstitution of cytochrome P-450 LM2-dependent activities, 134
 Chavoix, C., *see* Brouillet, E., 445
 Cherqui, G., *see* Kadiri, C., 418
 Christophe, J., *see* Waelbroeck, M., 267
 Chu, C. K., *see* Zhu, Z., 929
 Chu, E., Lai, G.-M., Zinn, S., and Allegra, C. J. Resistance of a human ovarian cancer line to 5-fluorouracil associate with decreased levels of 5-fluorouracil in DNA, 410
 Chubb, S., *see* Heinemann, V., 567
 Clark, M. A., *see* West, R. E., Jr., 610
 Clark, R. B., *see* Johnson, J. A., 289
 Cohen, M. L., *see* Baez, M., 31
 Colby, C., B., *see* Zhu, Z., 929
 Collins, S., *see* Lorenz, W., 599
 Compton, D. R., *see* Reggio, P. H., 854
 Contreras, M. L., *see* Shafer, T. J., 102
 Correia, M. A., *see* Bornheim, L., 319
 Costa, E., *see* Szekely, A. M., 624
 Costa, P., *see* Omiecinski, C. J., 462
 Coughenour, L. L., *see* Bruns, R. F., 950
 Courtland, G. G., *see* Bruns, R. F., 950
 Cragoe, E. J., Jr., *see* Taglialatela, M., 393
 Craig, P. I., Mehta, I., Murray, M., McDonald, D., Aström, A., van der Meide, P. H., and Farrell, G. C. Interferon down regulates the male-specific cytochrome P450III_{A2} in rat liver, 313
 Cribb, A. E., Miller, M., Tesoro, A., Spielberg, S. P. Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from human and dogs, 744
- D**
- Dacquet, C., *see* Martin, C., 667
 Datta, R., Kharbanda, S., and Kufe, D. Regulation of *jun*-B gene expression by 1- β -D-arabinofuranosylcytosine in human myeloid leukemia cells, 435
 Dawson, T. L., Nicholas, R. A., and Dingledine, R. Homomeric GluR1 excitatory amino acid receptors expressed in *Xenopus* oocytes, 779
 Delen, F. M., *see* Ehlert, F. J., 143
 DePalo, L. R., *see* Reagan, L. P., 878
 De Prost, D., Ollivier, V., and Hakim, J. Pentoxifylline inhibition of procoagulant activity generated by activated mononuclear phagocytes, 562
 Dichter, M., *see* Wang, H.-L., 357
 Dillon, T. P., *see* Von Geldern, T. W., 771
 Dilollo, D. L., Beilharz, W., Lai, M. C., and Minchin, R. F. Difluoromethylornithine prevents the down-regulation of type I interferon receptors: A possible mechanism for a synergistic antiproliferative effect, 451
 Dingledine, R., *see* Dawson, T. L., 779
 Di Renzo, G., *see* Taglialatela, M., 385, 393
 Dixon, R. A. F., *see* Johnson, J. A., 289
 Djurhuus, R., Svoldal, A. M., and Ueland, P. M. Cysteamine increases homocysteine export and glutathione content by independent mechanisms in C3H/10T1/2 cells, 327
 Dodd, J. H., *see* Bruns, R. F., 950
 Dolphin, A. C., *see* Scott, R. H., 711
 Dörje, F., *see* Wess, J., 517
 Dudley, D. T., Panek, R. L., Major, R. C., Lu, G. H., Bruns, R. F., Klinkefus, B. A., Hodges, J. C., and Weishaar, R. E. Subclasses of angiotensin II binding sites and their functional significance, 370
 Dumont, Y., *see* Martel, J.-C., 494
 Dunwiddie, T. V., *see* Leidenheimer, N. J., 823
- E**
- Egan, R. W., *see* West, R. E., Jr., 610
 Ehlert, F. J., and Delen, F. M. Influence of pH on the binding of scopolamine and *N*-methylscopolamine to muscarinic receptors in the corpus striatum and heart of rats, 143
 Ehlert, F. J., and Rathbun, B. E. Signaling through the muscarinic receptor-adenylate cyclase system of the heart is buffered against GTP over a range of concentrations, 148
 Ehlert, F. J., *see* Candell, L. M., 689
 El-Fakahany, E. E., *see* Hu, J., 895
 Eling, T. E., *see* Glasgow, W. C., 503
 Emini, E. A., *see* Goldman, M. E., 20
 Eng, W. K., McCabe, F. L., Tan, K. B., Mattern, M. R., Hofmann, G., Woessner, R. D., Hertzberg, R. P., and Johnson, R. K. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content, 471
 Eriksson, S., *see* Törnevik, Y., 237
 Etienne, J., *see* Kadiri, C., 418
 Eyer, C. S., *see* Causey, K. M., 134
- F**
- Fager, R. S., *see* Plucinski, T. M., 114
 Fagni, L., *see* Manzoni, O., 1
 Farrell, G. C., *see* Craig, P. I., 313
 Favreau, I., *see* Guillemette, G., 841
 Feindel, W., *see* Skalski, V., 299
 Fergus, J. H., *see* Bruns, R. F., 939, 950
 Fernandez-Larson, R., and Patterson, J. L. Ribavirin is an inhibitor of human immunodeficiency virus reverse transcriptase, 766
 Fischmeister, R., and Hartzell, H. C. Regulation of calcium current by low- K_m cyclic AMP phosphodiesterases in cardiac cells, 426
 Fischmeister, R., *see* Boutjdir, M., 758
 Fisher, S. K., Heacock, A. M., Seguin, E. B., and Agranoff, B. W. Polyphosphoinositides are the major source of inositol phosphates in carbamoylcholine-stimulated SK-N-SH neuroblastoma cells, 54
 Fluharty, S. J., *see* Campbell, M. D., 282
 Fluharty, S. J., *see* Reagan, L. P., 878
 Forest, M., *see* Martel, J.-C., 494
 Förstermann, U., Gorsky, L. D., Pollock, J. S., Ishii, K., Schmidt, H. H. W., Heller, M., and Murad, F. Hormone-induced biosynthesis of endothelium-derived relaxing factor/nitric oxide-like material in N1E-115 neuroblastoma cells requires calcium and calmodulin, 7
 Fournier, A., *see* Martel, J.-C., 494
 Fredholm, B. B., *see* Gerwins, P., 660
 Frelin, C., Vigne, P., and Breittmayer, J.-P. Mechanism of the cardiotoxic action of palytoxin, 904
 Friedman, J., *see* Johnson, J. A., 289
- G**
- Gaginella, T. S., *see* Kachur, J. F., 836
 Galas, M.-C., *see* Rodriguez, M., 333
 Ganey, P., *see* Wu, Y.-R., 128
 Ganey, P. E., Takei, Y., Kauffman, F. C., and Thurman, R. G. Ethanol potentiates oxygen uptake and toxicity due to menadione bisulfite in perfused rat liver, 959
 Gao, Y., *see* Booth, R. G., 92
 Gerhardt, M. A., Wade, S. M., and Neubig, R. R. *p*-[¹²⁵I]iodoclonidine is a partial agonist at the α_2 -adrenergic receptor, 214
 Gerwins, P., Nordstedt, C., and Fredholm, B. B. Characterization of adenosine A₁ receptors in intact DDT₁ MF-2 smooth muscle cells, 660
 Glasgow, W. C., and Eling, T. E. Epidermal growth factor stimulates linoleic acid metabolism in BALB/c 3T3 fibroblasts, 503

- Glaum, S. R., *see* Bleakman, D., 785
 Glossmann, H., *see* Zernig, G., 362
 Glover, E., *see* Poland, A., 306
 Goldman, M. E., Salituro, G. S., Bowen, J. A., Williamson, J. M., Zink, D. L., Schleif, W. A., and Emmini, E. A. Inhibition of human immunodeficiency virus-1 reverse transcriptase activity by rubromycines: Competitive interaction at the template primer site, 20
 Goldstein, G., *see* Lukas, R. J., 887
 Gorsky, L. D., *see* Förstermann, U., 7
 Grayson, D. R., *see* Szekely, A. M., 624
 Graziadei, I., *see* Zernig, G., 362
 Green, R. D., *see* Leung, E., 72
 Grindey, G. B., *see* Heinemann, V., 567
 Gros, P., *see* Skalski, V., 299
 Guengerich, F. P., *see* Wrighton, S. A., 207
 Guenther, T. M., *see* Wheeler, C. W., 634
 Guillemin, G., Favreau, I., Boulay, G., and Potier, M. Solubilization and partial characterization of inositol 1,4,5-trisphosphate receptor of bovine adrenal cortex reveal similarities with the receptor of rat cerebellum, 841
 Gustafsson, J.-Å., *see* Westin, S., 192
 Guzelian, P. S., *see* Kocarek, T. A., 440

H

- Haaseth, R. C., *see* Mosberg, H. I., 924
 Hahner, L. D., *see* Leidenheimer, N. J., 823
 Hakim, J., *see* De Prost, D., 562
 Hanf, R., *see* Boutjdir, M., 758
 Hansen, A. J., *see* Srivastava, G., 486
 Hanssen, B. R., *see* Lindstrom, T. D., 829
 Hantraye, P., *see* Brouillet, E., 445
 Harris, R. A., *see* Leidenheimer, N. J., 823
 Harrison, B. L., *see* Baron, B. M., 554
 Hartig, P. R., *see* Branchek, T., 604
 Hartig, P. R., *see* Weinshank, R. L., 681
 Hartzell, H. C., *see* Fischmeister, R., 426
 Hashimoto, K., *see* Suzuki, E., 725
 Hassett, C., *see* Omiecinski, C. J., 462
 Heacock, A. M., *see* Fisher, S. K., 54
 Heinemann, V., Xu, Y.-Z., Chubb, S., Sen, A., Hertel, L. W., Grindey, G. B., and Plunkett, W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine, 567
 Heller, M., *see* Förstermann, U., 7
 Hergl, A., *see* Paukovits, W. R., 401
 Hertel, L. W., *see* Heinemann, V., 567
 Hertzberg, R. P., *see* Eng, W. K., 471
 Heyl, D. L., *see* Mosberg, H. I., 924
 Highet, R. J., *see* Monks, T. J., 121
 Higuchi, H., Iwasa, A., Yoshida, H., and Miki, N. Long lasting increase in neuropeptide Y gene expression in rat adrenal gland with reserpine treatment: Positive regulation of transsynaptic activation and membrane depolarization, 614
 Hodges, J. C., *see* Dudley, D. T., 370
 Hoffman, B. J., *see* Teitler, M., 594
 Hofmann, G., *see* Eng, W. K., 471
 Holleman, W. H., *see* Von Geldern, T. W., 771
 Holst, M. A., *see* Von Geldern, T. W., 771
 Horn, R., *see* Korn, S. J., 524
 Hu, J., and El-Fakahany, E. E. Selectivity of McN-A-343 in stimulating phosphoinositide hydrolysis mediated by M₁-muscarinic receptors, 895

I

- Imai, S.-I., *see* Kitamura, Y., 184
 Imanishi, N., *see* Komuro, Y., 378
 Ishii, K., *see* Förstermann, U., 7

- Iwasa, A., *see* Higuchi, H., 614
 Iwasaki, M., *see* Wrighton, S. A., 207

J

- Jacobson, K. A., *see* Barrington, W. W., 177
 Jacobson, K. A., *see* Leung, E., 72
 Jacobson, K. L., *see* Watson, E. L., 547
 Jaxel, C., *see* Wassermann, K., 38
 Jmari, K., *see* Martin, C., 667
 Johnson, B. G., *see* Schoepp, D. D., 222
 Johnson, J. A., Clark, R. B., Friedman, J., Dixon, R. A. F., and Strader, C. D. Identification of a specific domain in the β -adrenergic receptor required for phorbol ester-induced inhibition of catecholamine-stimulated adenylyl cyclase, 289
 Johnson, K. M., *see* Sacaan, A. I., 705
 Johnson, R. A., *see* Bushfield, M., 848
 Johnson, R. K., *see* Eng, W. K., 471
 Jordan, V. C., *see* Murphy, C. S., 737

K

- Kachur, J. F., Sturm, B. L., Gaginella, T. S., and Noronha-Blob, L. Regulation of guinea pig ileal electrolyte transport by M₃ muscarinic acetylcholine receptors *in vitro*, 836
 Kadiri, C., Cherqui, G., Masliah, J., Rybkine, T., Etienne, J., and Béréziat, G. Mechanism of N-formyl-methionyl-leucyl-phenylalanine- and platelet-activating factor-induced arachidonic acid release in guinea pig alveolar macrophages: Involvement of a GTP-binding protein and role of protein kinase A and protein kinase C, 418
 Kamataki, T., *see* Uchida, T., 644
 Kamatchi, G. L., and Ticku, M. K. Functional coupling of presynaptic GABA_A receptors with voltage-gated Ca²⁺ channel: Regulation by protein kinases A and C in cultured spinal cord neurons, 342
 Kao, H.-T., *see* Branchek, T., 604
 Kauffman, F. C., *see* Ganey, P. E., 959
 Kauffman, F. C., *see* Wu, Y.-R., 128
 Kemp, D. E., *see* Weiss, S., 229
 Khalili-Varasteh, M., *see* Brouillet, E., 445
 Kharbanda, S., *see* Datta, R., 435
 Kiso, Y., *see* Von Geldern, T. W., 771
 Kitada, M., *see* Uchida, T., 644
 Kitamura, Y., Imai, S.-I., Matsueda, R., and Nomura, Y. Effects of sulfhydryl-modifying reagents, 3-nitro-2-pyridinesulfonyl compounds, on the coupling between inhibitory receptors and GTP-binding proteins G_i/G_o in rat brain membranes, 184
 Klinkefus, B. A., *see* Dudley, D. T., 370
 Klueppelberg, U. G., Molero, X., Barrett, R. W., and Miller, L. J. Biochemical characterization of the cholecystokinin receptor on CHP212 human neuroblastoma cells, 159
 Knecht, K. T., Bradford, B. U., Mason, R. P., and Thurman, R. G. *In vivo* formation of a free radical metabolite of ethanol, 26
 Kocarek, T. A., Schuetz, E. G., and Guzelian, P. S. Differentiated induction of cytochrome P450b/e and P450p mRNAs by dose of phenobarbital in primary cultures of adult rat hepatocytes, 440
 Kohn, K. W., *see* Wasserman, K., 38
 Komori, M., *see* Uchida, T., 644
 Komuro, Y., Imanishi, N., Uchida, M., and Morooka, S. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661, 378
 Kopriva, D., *see* Skalski, V., 299
 Korbonts, D., *see* Orosz, F., 910
 Korn, S. J., and Horn, R. Nordihydroguaiaretic acid inhibits voltage-activated Ca²⁺ currents independently of lipoxygenase inhibition, 524
 Kotlikoff, M. I., *see* Campbell, M. D., 282
 Kufe, D., *see* Datta, R., 435
 Kula, N. S., *see* Booth, R. G., 92

L

- Lai, G.-M., *see* Chu, E., 410
 Lai, M. C., *see* Dilollo, D. L., 451
 Landry, Y., *see* Bueh, J.-L., 816
 Langan-Fahey, S. M., *see* Murphy, C. S., 737
 Lau, S. S., *see* Monks, T. J., 121
 Lazareno, S., Buckley, N. J., and Roberts, F. F. Characterization of muscarinic M₄ binding sites in rabbit lung, chicken heart, and NG108-15 cells, 805
 Lefkowitz, R. J., *see* Lorenz, W., 599
 Leidenheimer, N. J., Browning, M. D., Dunwiddie, T. V., Hahner, L. D., and Harris, R. A. Phosphorylation-independent effects of second messenger system modulators on γ -aminobutyric acid_A receptor complex function, 823
 Leonhardt, S., *see* Teitler, M., 594
 Leung, E., Jacobson, K. A., and Green, R. D. Analysis of agonist-antagonist interactions at A₁ adenosine receptors, 72
 Li, L., *see* Ochoa, E. L. M., 863
 Lichtblau, H., *see* Weinshank, R. L., 681
 Lignon, M.-F., *see* Rodriguez, M., 333
 Liliom, K., *see* Orosz, F., 910
 Linden, J., *see* Munshi, R., 170
 Lindstrom, T. D., Hanssen, B. R., and Bendele, A. M. Effects of hepatic ischemia-reperfusion injury on the hepatic mixed function oxidase system in rats, 829
 Lomasney, J. W., *see* Lorenz, W., 599
 Lorenz, W., Lomasney, J. W., Collins, S., Regan, J. W., Caron, M. G., and Lefkowitz, R. J. Expression of three α_2 -adrenergic receptor subtypes in rat tissues: Implications for α receptor classification, 599
 Lu, G. H., *see* Dudley, D. T., 370
 Lucero, L., *see* Lukas, R. J., 887
 Lukas, R. J., Audhya, T., Goldstein, G., and Lucero, L. Interactions of the thymic polypeptide hormone thymopoietin with neuronal nicotinic α -bungarotoxin binding sites and with muscle-type, but not ganglia-type, nicotinic acetylcholine receptor ligand-gated ion channels, 887
- M
- Macchi, M., *see* Branchek, T., 604
 Macchi, M., *see* Weinshank, R. L., 681
 Madeddu, L., *see* Rosenthal, L., 919
 Mailer, C., *see* Woods, J. S., 253
 Maines, M. D. Multiple forms of biliverdin reductase: Age-related change in pattern of expression rat liver and brain, 481
 Major, R. C., *see* Dudley, D. T., 370
 Mante, S., and Minneman, K. P. Is adenosine involved in inhibition of forskolin-stimulated cyclic AMP accumulation by caffeine in rat brain?, 652
 Manzoni, O., Fagni, L., Pin, J.-P., Rassendren, F., Poulat, F., Sladeczek, F., and Bockaert, J. (*trans*)-1-Amino cyclopentyl-1,3-dicarboxylate stimulates quisqualate phosphoinositide-coupled receptors but not ionotropic glutamate receptors in striatal neurons and *xenopus* oocytes, 1
 Markovits, J., *see* Wassermann, K., 38
 Martel, J.-C., Fournier, A., St-Pierre, S., Dumont, Y., Forest, M., and Quirion, R. Comparative structural requirements of brain neuropeptide Y binding sites and vas deferens neuropeptide Y receptors, 494
 Martin, B. R., *see* Reggio, P. H., 854
 Martin, C., Arnaudeau, S., Jmari, K., Rakotoarisoa, L., Sayet, I., Dacquet, C., Mironneau, C., and Mironneau, J. Identification and properties of voltage-sensitive sodium channels in smooth muscle cells from pregnant rat myometrium, 667
 Martinez, J., *see* Rodriguez, M., 333
 Masliah, J., *see* Kadiri, C., 418
 Mason, R. P., *see* Knecht, K. T., 26
 Matsueda, R., *see* Kitamura, Y., 184
 Mattern, M. R., *see* Eng, W. K., 471
 May, B. K., *see* Srivastava, G., 486
 Maziere, M., *see* Brouillet, E., 445
 McCabe, F. L., *see* Eng, W. K., 471
 McCague, R., *see* Murphy, C. S., 737
 McDonald, D., *see* Craig, P. I., 313
 McDonald, I. A., *see* Baron, B. M., 554
 McNamara, J. O., *see* Yeh, G.-C., 14
 McNamee, M. G., *see* Ochoa, E. L. M., 863
 McPhee, C., *see* Watson, E. L., 547
 McQuaid, L. A., *see* Schoepp, D. D., 222
 Medzihradsky, F., *see* Mosberg, H. I., 924
 Mehta, A. K., *see* Ticku, M. K., 719
 Mehta, I., *see* Craig, P. I., 313
 Meldolesi, J., *see* Rosenthal, L., 919
 Méry, P.-F., *see* Boutjdir, M., 758
 Miki, N., *see* Higuchi, H., 614
 Miller, F. P., *see* Baron, B. M., 554
 Miller, L. J., *see* Klueppelberg, U. G., 159
 Miller, M., *see* Cribb, A. E., 744
 Miller, R. J., *see* Bleakman, D., 785
 Minchin, R. F., *see* Dilollo, D. L., 451
 Minneman, K. P., *see* Mante, S., 652
 Minneman, K. P., *see* Wilson, K. M., 274
 Mir, R., *see* Reagan, L. P., 878
 Mironneau, C., *see* Martin, C., 667
 Mironneau, J., *see* Martin, C., 667
 Molero, X., *see* Klueppelberg, U. G., 159
 Molowa, D. T., *see* Wrighton, S. A., 207
 Monks, T. J., Highet, R. J., and Lau, S. S. Oxidative cyclization, 1,4-benzothiazine formation and dimerization of 2-bromo-3-(glutathion-S-yl)hydroquinone, 121
 Morooka, S., *see* Komuro, Y., 378
 Mosberg, H. I., Heyl, D. L., Haaseth, R. C., Omnaas, J. R., Medzihradsky, F., and Smith, C. B. Cyclic dermorphin-like tetrapeptides with δ -opioid receptor selectivity. 3. Effect of residue 3 modification on *in vitro* opioid activity, 924
 Moshhammer, T., *see* Zernig, G., 362
 Munshi, R., and Linden, J. Interaction of purified bovine brain A₁-adenosine receptors with guanine nucleotide-binding proteins of human platelet membranes following reconstitution, 170
 Murad, F., *see* Förstermann, U., 7
 Murphy, C. S., Langan-Fahey, S. M., McCague, R., Jordan, V. C. Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells *in vitro*, 737
 Murray, M., *see* Craig, P. I., 313
 Musilková, J., *see* Tuček, S., 674
- N
- Nedoma, J., *see* Tuček, S., 674
 Neubig, R. R., *see* Gerhardt, M. A., 214
 Nicholas, R. A., *see* Dawson, T. L., 779
 Nomura, Y., *see* Kitamura, Y., 184
 Nordstedt, C., *see* Gerwins, P., 660
 Noronha-Blob, L., *see* Kachur, J. F., 836
 Novosad, E. I., *see* Von Geldern, T. W., 771
- O
- Ochoa, E. L. M., Li, L., Plummer, A., and McNamee, M. G. Direct effects of thymopentin (Arg-Lys-Asp-Val-Tyr) on cholinergic agonist-induced slow inactivation of nicotinic acetylcholine receptor function, 863
 Ollivier, V., *see* De Prost, D., 562
 Olsen, L. D., *see* Cashman, J. R., 573

Omicinski, C. J., Hassett, C., and Costa, P. Developmental expression and *in situ* localization of the phenobarbital-inducible rat hepatic mRNAs for cytochromes CYP2B1, CYP2B2, CYP2C6, and CYP3A1, 462

Omnaas, J. R., *see* Mosberg, H. I., 924

Oppenorth, T. J., *see* Von Geldern, T. W., 771

Orosz, F., Telegdi, M., Liliom, K., Solti, M., Korbonits, D., and Ovádi, J. Dissimilar mechanisms of action of anticalmodulin drugs: Quantitative analysis, 910

Ovádi, J., *see* Orosz, F., 910

P

Palfreyman, M. G., *see* Baron, B. M., 554

Panasci, L. C., *see* Skalski, V., 299

Panek, R. L., *see* Dudley, D. T., 370

Park, S. S., *see* Wheeler, C. W., 634

Patterson, J. L., *see* Fernandez-Larson, R., 766

Paukovits, W. R., Hergl, A., and Schulte-Herman, R. Hemoregulatory peptide pGlu-Glu-Asp-Cys-Lys: A new synthetic derivative for avoiding dimerization and loss of inhibitory activity, 401

Peroutka, S. J., *see* Schmidt, A. W., 511

Pin, J.-P., *see* Manzoni, O., 1

Plucinski, T. M., Fager, R. S., and Reddy, G. P. V. Allosteric interaction of components of the replisome complex is responsible for enzyme cross-inhibition, 114

Plummer, A., *see* Ochoa, E. L. M., 863

Plunkett, W., *see* Heinemann, V., 567

Poland, A., and Glover, E. Characterization and strain distribution pattern, of the murine Ah receptor specified by the Ah^d and Ah^{b-3} alleles, 306

Pollock, J. S., *see* Förstermann, U., 7

Pommier, Y., *see* Wasserman, K., 38

Potier, M., *see* Guillemette, G., 841

Poulat, F., *see* Manzoni, O., 1

Prescott, W. R., Jr., *see* Reggio, P. H., 854

Proška, J., *see* Tuček, S., 674

Prozialeck, W. C., *see* Zhang, S., 698

Pugaley, T. A., *see* Bruns, R. F., 950

Q

Qu, W., *see* Wu, Y.-R., 128

Quirion, R., *see* Martel, J.-C., 494

R

Rabe, C. S., and Tabakoff, B. Glycine site-directed agonists reverse the actions of ethanol at the *N*-Methyl-D-aspartate receptor, 753

Rakotoarisoa, L., *see* Martin, C., 667

Rassendren, F., *see* Manzoni, O., 1

Rathbun, B. E., *see* Ehler, F. J., 148

Raucy, J. L., *see* Wrighton, S. A., 207

Rauscher, F. J., III, Beerman, T. A., and Baker, R. M. Characterization of auroomycin-resistant hamster cell mutants that display a multidrug resistance phenotype, 198

Reagan, L. P., Ye, X., Mir, R., DePalo, L. R., and Fluharty, S. J. Up-regulation of angiotensin II receptors by *in vitro* differentiation of murine N1E-115 neuroblastoma cells, 878

Reddy, G. P. V., *see* Plucinski, T. M., 114

Regan, J. W., *see* Lorenz, W., 599

Reggio, P. H., Seltzman, H. H., Compton, D. R., Prescott, W. R., Jr., and Martin, B. R. Investigation of the role of the phenolic hydroxyl in cannabinoid activity, 854

Reider, N., *see* Zernig, G., 362

Reisine, T., *see* Wang, H.-L., 357

Resnik, T. J., Scott-Burden, T., Boulanger, C., Weber, E., and Bühler, F. R. Internalization of endothelin by cultured human vascular smooth muscle cells: Characterization and physiological significance, 244

Roberts, F. F., *see* Lazareno, S., 805

Robinson, B. H., *see* Woods, J. S., 253

Rodriguez, M., Lignon, M.-F., Galas, M.-C., Amblard, M., and Martinez, J. Cyclic cholecystokinin analogues that are highly selective for rat and guinea pig central cholecystokinin receptors, 333

Rosenthal, L., Zacchetti, D., Madeddu, L., and Meldolesi, J. Mode of action of α -latrotoxin: Role of divalent cations in Ca^{2+} -dependent and Ca^{2+} -independent effects mediated by the toxin, 919

Roskoski, R., Jr., Wilgus, H., and Vrana, K. E. Inactivation of tyrosine hydroxylase by pterin substrates following phosphorylation by cyclic AMP-dependent protein kinase, 541

Rouot, B., *see* Bueb, J.-L., 816

Rybkin, T., *see* Kadiri, C., 418

S

Sacaan, A. I., and Johnson, K. M. Competitive inhibition of magnesium-induced [3H]N-(1-[theinyl]cyclohexyl)piperidine binding by arcaine: Evidence for a shared spermidine-magnesium binding site, 705

Salituro, F. G., *see* Baron, B. M., 554

Salituro, W. A., *see* Goldman, M. E., 20

Sari, M.-A., *see* Wrighton, S. A., 207

Sayet, I., *see* Martin, C., 667

Schinazi, R. F., *see* Zhu, Z., 929

Schleif, W. A., *see* Goldman, M. E., 20

Schmidt, A. W., and Peroutka, S. J. Quantitative molecular analysis predicts 5-hydroxytryptamine receptor binding affinity, 511

Schmidt, C. J., *see* Baron, B. M., 554

Schmidt, H. H. H. W., *see* Förstermann, U., 7

Schoepp, D. D., Johnson, B. G., Smith, E. C. R., and McQuaid, L. A. Stereoselectivity and mode of inhibition of phosphoinositide-coupled excitatory amino acid receptors by 2-amino-3-phosphonopropionic acid, 222

Schuetz, E. G., *see* Kocarek, T. A., 440

Schulte-Herman, R., *see* Paukovits, W. R., 401

Scott, R. H., Dolphin, A. C., Bindokas, V. P., and Adams, M. E. Inhibition of neuronal Ca^{2+} channel currents by the funnel web spider toxin ω -aga-1A, 711

Scott-Burden, T., *see* Resnik, T. J., 244

Seguin, E. B., *see* Fisher, S. K., 54

Seltzman, H. H., *see* Reggio, P. H., 854

Sen, A., *see* Heinemann, V., 567

Shafer, T. J., Contreras, M. L., and Atchison, W. D. Characterization of interactions of methylmercury with Ca^{2+} channels in synaptosomes and pheochromocytoma cells: Radiotracer flux and binding studies, 102

Sharma, V. K., *see* Vamvakas, S., 455

Shel-Kovnikov, S., *see* Tuček, S., 674

Sheu, S.-S., *see* Vamvakas, S., 455

Shih, N.-Y., *see* West, R. E., Jr., 610

Shoshani, I., *see* Bushfield, M., 848

Shrier, A., *see* Boutjdir, M., 758

Sibley, D. R., *see* Barton, A. C., 531

Siegel, B. W., *see* Baron, B. M., 348

Siegel, M. E., *see* West, R. E., Jr., 610

Singh, J. C., *see* Watson, E. L., 547

Skalski, V., Yarosh, D. B., Batist, G., Gros, P., Feindel, W., Kopriva, D., and Panasci, L. C. Mechanisms of resistance to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) in sensitive and resistant human glioma cells, 299

Smith, C. B., *see* Mosberg, H. I., 924

Smith, E. C. R., *see* Schoepp, D. D., 222

Solti, M., *see* Orosz, F., 910

Sommadosi, J.-P., *see* Weidner, D. A., 797

Sommadosi, J.-P., *see* Zhu, Z., 929

Sorensen, C. J., *see* Baron, B. M., 554

Spielberg, S. P., *see* Cribb, A. E., 744

- Srivastava, G., Hansen, A. J., Bawden, M. J., and May, B. K. Hemine administration to rats reduces levels of hepatic mRNAs for phenobarbitone-inducible enzymes, 486
- Stiles, G. L., *see* Barrington, W. W., 177
- St-Pierre, S., *see* Martel, J.-C., 494
- Strader, C. D., *see* Johnson, J. A., 289
- Ström, A., *see* Westin, S., 192
- Strum, B. L., *see* Kachur, J. F., 836
- Subramaniam, S., *see* Campbell, M. D., 282
- Suzuki, E., Tsujimoto, G., Tamura, K., and Hashimoto, K. Two pharmacologically distinct α_1 adrenoceptor subtypes in the contraction of rabbit aorta: Each subtype couples with a different Ca^{2+} signaling mechanism and plays a different physiological role, 725
- Svardal, A. M., *see* Djurhuus, R., 327
- Szekely, A. M., Costa, E., and Grayson, D. R. Transcriptional program coordination by *N*-methyl-D-aspartate-sensitive glutamate receptor stimulation in primary cultures of cerebellar neurons, 624

T

- Tabakoff, B., *see* Rabe, C. S., 753
- Tagliatela, M., Canzoniero, L. M. T., Cragoe, E. J., Jr., Di Renzo, G., and Annunziato, L. Na^+ - Ca^{2+} exchange in central nerve endings. II. Relationship between pharmacological blockade by amiloride analogues and dopamine release from tuberofundibular hypothalamic neurons, 393
- Tagliatela, M., Di Renzo, G., and Annunziato, L. Na^+ - Ca^{2+} exchange activity in central nerve endings. I. Ionic conditions that discriminate $^{45}\text{Ca}^{2+}$ uptake through the exchanger from that occurring through voltage-operated Ca^{2+} channels, 385
- Takei, Y., *see* Ganey, P. E., 959
- Tamura, K., *see* Suzuki, E., 725
- Tan, K. B., *see* Eng, W. K., 471
- Tastenoy, M., *see* Waelbroeck, M., 267
- Teitler, M., Leonhardt, S., Weisberg, E. L., and Hoffman, B. J. 4-[125]iodo-(2,5-dimethoxy)phenylisopropylamine and [^3H]ketanserin labeling of 5-hydroxytryptamine $_2$ (5HT $_2$) receptors in mammalian cells transfected with a rat 5HT $_2$ cDNA: Evidence for multiple states and not multiple 5HT $_2$ receptor subtypes, 594
- Telegdi, M., *see* Orosz, F., 910
- Tephly, R. R., *see* Thomassin, J., 294
- Tesoro, A., *see* Cribb, A. E., 744
- Thayer, S. A., *see* Bleakman, D., 785
- Thomassin, J., and Tephly, R. R. Photoaffinity labeling of rat liver microsomal morphine UDP-glucuronosyltransferase by [^3H]flunitrazepam, 294
- Thurman, R., *see* Wu, Y.-R., 128
- Thurman, R. G., *see* Ganey, P. E., 959
- Thurman, R. G., *see* Knecht, K. T., 26
- Ticku, M. K., and Mehta, A. K. γ -Aminobutyric acid $_A$ receptor desensitization in mice spinal cord cultured neurons: Lack of involvement of protein kinases A and C, 719
- Ticku, M. K., *see* Kamatchi, G. L., 342
- Tinney, F. J., *see* Bruns, R. F., 950
- Törnevik, Y., and Eriksson, S. 2',3'-Dideoxycytidine toxicity in cultured human CEM T lymphoblasts: Effects of combination with 3'-azido-3'-deoxythymidine and thymidine, 237
- Tran, L. L. P., *see* Candell, L. M., 689
- Trudell, J. R., Ardies, C. M., and Anderson, W. R. Cross-reactivity of antibodies raised against acetaldehyde adducts of protein with acetaldehyde adducts of phosphatidyl-ethanolamine: Possible role in alcoholic cirrhosis, 587
- Truong, A. T., *see* Ballatori, N., 64
- Tse, F. W. Y., *see* Weiss, S., 229
- Tsujimoto, G., *see* Suzuki, E., 725
- Tuček, S., Musilková, J., Nedoma, J., Proška, J., Shel-Kovnikov, S., Vorlíček, J. Positive cooperativity in the binding of alcuronium and *N*-methylscopolamine to muscarinic acetylcholine receptors, 674

U

- Uchida, M., *see* Komuro, Y., 378
- Uchida, T., Komori, M., Kitada, M., and Kamataki, T. Isolation of cDNAs coding for three different forms of liver microsomal cytochrome P-450 from polychlorinated biphenyl-treated beagle dogs, 644
- Ueland, P. M., *see* Djurhuus, R., 327

V

- Vamvakas S., Sharma, V. K., Sheu, S.-S., and Anders, M. W. Perturbations of intracellular calcium distribution in kidney cells by nephrotoxic haloalkenyl cysteine *S*-conjugates, 455
- Vandenbranden, M., *see* Wrighton, S. A., 207
- van der Meide, P. H., *see* Craig, P. I., 313
- Vigne, P., *see* Frelin, C., 904
- Voliček, J., *see* Tuček, S., 674
- Von Geldern, T. W., Budzik, G. P., Dillon, T. P., Holleman, W. H., Holst, M. A., Kiso, Y., Novosad, E. I., Opgenorth, T. J., Rockway, T. W., Thomas, A. M., and Yeh, S. Atrial natriuretic peptide antagonists: Biological evaluation and structural correlations, 771
- Vrana, K. E., *see* Roskoski, R., Jr, 541

W

- Wade, S. M., *see* Gerhardt, M. A., 214
- Waelbroeck, M., Tastenoy, M., Camus, J., and Christophe, J. Binding of selective antagonists to four muscarinic receptors (M_1 to M_4) in rat forebrain, 267
- Wang, H.-L., Dichter, M., and Reisine, T. Lack of cross-desensitization of somatostatin-14 and somatostatin-28 receptors coupled to potassium channels in rat neocortical neurons, 357
- Wassermann, K., Markovits, J., Jaxel, C., Capranico, G., Kohn, K. W., and Pommier, Y. Effects of Morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian, DNA topoisomerases I and II, 38
- Watson, E. L., Singh, J. C., McPhee, C., Beavo, J., and Jacobson, K. L. Regulation of cAMP metabolism in mouse parotid gland by cGMP and calcium, 547
- Weber, E., *see* Resnik, T. J., 244
- Weidner, D. A., and Sommadossi, J.-P. 3'-Azido-3'-deoxythymidine inhibits globin gene transcription in butyric acid-induced K-562 human leukemia cells, 797
- Weinshank, R. L., Zgombick, J. M., Macchi, M., Adham, N., Lichtblau, H., Branchek, T. A., and Hartig, P. R. Cloning, expression, and pharmacological characterization of a human α_{2B} -adrenergic receptor, 681
- Weisberg, E. L., *see* Teitler, M., 594
- Weishaar, R. E., *see* Dudley, D. T., 370
- Weiss, B., *see* Zhang, S., 698
- Weiss, S., Kemp, D. E., Bause, L., and Tse, F. W. Y. Kainate receptors coupled to the evoked release of [^3H]- γ -aminobutyric acid from striatal neurons in primary culture: Potentiation by lithium ions, 229
- Wess, J., Bonner, T. I., and Brann, M. R. Chimeric m2/m3 muscarinic receptors: Role of carboxyl terminal receptor domains in selectivity of ligand binding and coupling to phosphoinositide hydrolysis, 872
- Wess, J., Bonner, T. I., Dörje, F., and Brann, M. R. Delineation of muscarinic receptor domains conferring selectivity of coupling to guanine nucleotide-binding proteins and second messengers, 517
- West, R. E., Jr., Zweig, A., Shih, N.-Y., Siegel, M. I., Egan, R. W., and Clark, M. A. Identification of two H_3 -histamine receptor subtypes, 610
- Westin, S., Ström, A., Gustafsson, J.-Å., and Zaphiropoulos, P. G. Growth hormone regulation of the cytochrome P-450IIC subfamily in the rat: Inductive, repressive, and transcriptional effects on P-450f (IIC7) and P-450 $_{PB1}$ (IIC6) gene expression, 192
- Wheeler, C. W., Park, S. S., and Guenther, T. M. Immunochemical analysis of a cytochrome P-450IA1 homologue in human lung microsomes, 634

- White, H. S., *see* Baron, B. M., 554
 Wilgus, H., *see* Roskoski, R., Jr, 541
 Williams, G. J., *see* Zhu, Z., 929
 Williamson, J. M., *see* Goldman, M. E., 20
 Williamson, J. R., *see* Campbell, M. D., 282
 Wilson, K. M., and Minneman, K. P. Pertussis toxin inhibits norepinephrine-stimulated inositol phosphate formation in primary brain cell cultures, 274
 Woessner, R. D., *see* Eng, W. K., 471
 Woods, J. S., Calas, C. A., Aicher, L. D., Robinson, B. H., and Mailer, C. Stimulation of porphyrinogen oxidation by mercuric ion. I. Evidence of free radical formation in the presence of thiols and hydrogen peroxide, 253
 Woods, J. S., Calas, C. A., and Aicher, L. D. Stimulation of porphyrinogen oxidation by mercuric ion. II. Promotion of oxidation from the interaction of mercuric ion, glutathione, and mitochondria-generated hydrogen peroxide, 261
 Wrighton, S. A., Brian, W. R., Sari, M.-A., Iwasaki, M., Guengerich, F. P., Raucy, J. L., Molowa, D. T., and Vandenbranden, M. Studies on the expression and metabolic capabilities of human liver cytochrome P450III_{A5} (HLP3), 207
 Wu, Y.-R., Kauffman, F. C., Qu, W., Ganey, P., and Thurman, R. G. Unique role of oxygen in regulation of hepatic monooxygenation and glucuronidation, 128

X

- Xu, Y.-Z., *see* Heinemann, V., 567

Y

- Yarosh, D. B., *see* Skalski, V., 299

- Ye, X., *see* Reagan, L. P., 878
 Yeh, G.-C., Bonhaus, D. W., and McNamara, J. O. Evidence that zinc inhibits *N*-methyl-D-aspartate receptor-gated ion channel activation by non-competitive antagonism of glycine binding, 14
 Yorke, J.-C., *see* Brouillet, E., 445
 Yoshida, H., *see* Higuchi, H., 614
 Yu, L., *see* Baez, M., 31
 Yun, S. H., *see* Candell, L. M., 689

Z

- Zacchetti, D., *see* Rosenthal, L., 919
 Zaphiropoulos, P. G., *see* Westin, S., 192
 Zech, C., *see* Zernig, G., 362
 Zernig, G., Graziadei, I., Moshhammer, T., Zech, C., Reider, N., and Glossmann, H. Mitochondrial Ca²⁺ antagonist binding sites are associated with an inner mitochondrial membrane anion channel, 362
 Zgombick, J. M., *see* Weinshank, R. L., 681
 Zhang, S., Prozialeck, W. C., Weiss, B. Differential inhibition of calcium-dependent and calmodulin-dependent enzymes by drug-calmodulin adducts, 698
 Zhu, Z., Schinazi, R. F., Chu, C. K., Williams, G. J., Colby, C. B., and Sommadossi, J.-P. Cellular metabolism of 3'-azido-2',3'-dideoxyuridine with formation of 5'-O-diphosphohexose derivatives by previously unrecognized metabolic pathways for 2'-deoxyuridine analogs, 929
 Zink, D. L., *see* Goldman, M. E., 20
 Zinn, S., *see* Chu, E., 410
 Zong, R., *see* Booth, R. G., 92
 Zweig, A., *see* West, R. E., Jr., 610

SUBJECT INDEX FOR VOLUME38

A

- Acetaldehyde, adducts, cross-reactivity of antibodies, alcoholic cirrhosis, 587
- Actinomycin D, morpholinyl doxorubicins and doxorubicin, mammalian DNA topoisomerases I and II, 38
- Action potentials, bradykinin-induced modulation of calcium signals, dorsal root ganglion neurons (rat), 785
- Adenosine, inhibition, forskolin-stimulated cyclic AMP accumulation, caffeine (rat), 652
- Adenylate cyclase
heterologous desensitization, prostaglandins, 46
p-[¹²⁵I]iodoclonidine, novel radiolabeled agonist, central α^2 -adrenergic receptors, 348
L-type Ca^{2+} currents, high affinity forskolin, cardiac cells, 758
muscarinic receptor signaling, heart (rat), 148
muscarinic receptor subtypes, phosphoinositide hydrolysis, ileum longitudinal muscle (rat), 689
- Adenylyl cyclase
activity in neuroblastoma cells, agonist-induced desensitization, D_1 -dopamine receptors, 531
catecholamine-stimulated, phorbol ester-induced inhibition, β -adrenergic receptor (mouse), 289
intracellular inhibitor, 3'-AMP, 848
- Adrenal cortex, bovine, inositol 1,4,5-trisphosphate receptors, rat cerebellum, 841
- Adrenal gland, neuropeptide Y gene expression, reserpine treatment (rat), 614
- Adrenal medulla, purinergic P_2 receptors, compared to aortic endothelium, 84
- Adrenoceptors
alpha-1, contraction of aorta (rabbit), 725
alpha-2
p-iodoclonidine, partial agonist, 214
3-nitro-2-pyridinesulfonyl compounds, brain membranes (rat), 184
novel radiolabeled agonist, *p*-[¹²⁵I]iodoclonidine, 348
subtypes, α_2 receptor classification (rat), 599
*alpha*_{2B}, cloning, pharmacological characterization, 681
beta, phorbol ester-induced inhibition, catecholamine-stimulated adenylyl cyclase (mouse), 289
3'-Adenosine monophosphate, tissue levels, source and regulation, intracellular inhibitor, adenylyl cyclases, 848
- Aging, -related change in expression, biliverdin reductase, liver and brain (rat), 481
- Alcohol, cirrhosis, cross-reactivity of antibodies, acetaldehyde adducts, 587
- Alcuronium, *N*-methylscopolamine and, binding to muscarinic acetylcholine receptors (rat), 674
- Alleles, *Ah^d* and *Ah^{b-3}*, strain distribution pattern, Ah receptor (mouse), 306
- Amiloride, analogues, Na^+ - Ca^{2+} exchange activity, central nerve endings (rat), 393
- γ -Aminobutyric acid, release from striatal neurons, kainate receptors (mouse), 229
- (*trans*)-1-Amino-cyclopentyl-1,3-dicarboxylate, quisqualate phosphoinositide-coupled receptors, striatal neurons, *Xenopus* oocytes, 1
- 2-Amino-3-benzoylthiophenes, enhancement of adenosine A_1 receptor binding, 939, 950
- 2-Amino-3-phosphonopropionic acid, stereoselectivity and mode of inhibition, phosphoinositide-coupled excitatory amino acid receptors (rat), 222
- Angiotensin II, subclasses of binding sites, functional significance, 370

Anthracyclines, morpholinyl doxorubicins and doxorubicin, Actinomycin D, mammalian DNA topoisomerases I and II, 38

Aorta

- contraction, α_1 -adrenoceptor subtypes (rabbit), 725
endothelium, purinergic P_2 receptors, 84
- Aphidicolin, enzyme cross-inhibition, allosteric interaction, replitase complex (Chinese hamster), 114
- Aporphines, stereoisomers, presynaptic dopamine inhibition, striatal tissue (rat), 92
- 1- β -D-Arabinofuranosylcytosine, regulation of *jun*-B gene expression, myeloid leukemia cells (human), 435
- Arachidonic acid
linoleic acid metabolism, epidermal growth factor, BALB/c 3T3 fibroblasts, 503
release, FMLP, alveolar macrophages (guinea pig), 418
- Arcaïne, Mg-induced *N*-(1-[thienyl]cyclohexyl)piperidine binding, competitive inhibition (rat), 705
- 2-Aryl-1,3-dithiolanes, stereoselective *S*-oxygenation, flavin-containing and cytochrome P-450 monooxygenases, 573
- Atrial natriuretic peptide, antagonists, 771
- Auromycin, -resistant hamster cell mutants, multidrug resistance phenotype, 198
- ω -Ava-IA, inhibition of neuronal Ca^{2+} channel currents, 711
- 3'-Azido-2',3'-dideoxyuridine, cellular metabolism, formation, 5'-*O*-diphosphohexose derivatives, 929
- 3'-Azido-3'-deoxythymidine
2',3'-dideoxycytidine toxicity, human CEM T lymphoblasts, 237
inhibition of globin gene transcription, butyric acid-induced K-562 cells (human), 797

B

- 1,4-Benzothiazine, formation, 2-bromo-3-(glutathion-*S*-yl)hydroquinone dimerization, oxidative cyclization, 121
- Bile, formation, hormones, paracellular permeability, 64
- Biliverdin reductase, multiple forms, age-related change in expression, liver and brain (rat), 481
- Bradykinin, -induced modulation of calcium signals, dorsal root ganglion neurons (rat), 785
- Brain
 A_1 -adenosine receptors, interaction with guanine nucleotide-binding proteins, platelet membranes, 170
age-related change in pattern of expression, biliverdin reductase (rat), 481
central cholecystokinin receptors, cyclic cholecystokinin analogues (rat, guinea pig), 333
cerebellar neurons, transcriptional program coordination, NMDA glutamate receptor (rat), 624
inhibition by caffeine, forskolin-stimulated cyclic AMP, adenosine (rat), 652
 Na^+ - Ca^{2+} exchange activity, central nerve endings (rat), 393
neuropeptide binding sites, vas deferens neuropeptide Y receptors (rat), 494
3-nitro-2-pyridinesulfonyl compounds, receptors and G proteins (rat), 184
pertussis toxin inhibition, norepinephrine-stimulated inositol phosphate formation (rat), 274
somatostatin-14 and somatostatin-28 receptors, lack of cross-sensitization, neocortical neurons (rat), 357
striatal neurons, GABA release, kainate receptors (mouse), 229
- Breast cancer, estrogen-responsive cells, proliferation, hydroxylated metabolites of tamoxifen, 737

- 1-(4-Bromo-2,5-dimethoxy)-4-bromoamphetamine, ketanserin and, affinity sites, cloned human 5-HT₁ receptor, 604
- 2-Bromo-3-(glutathion-*S*-yl)hydroquinone, dimerization, 1,4-benzothiazine formation, oxidative cyclization, 121
- α -Bungarotoxin, thymopoietin interactions, nicotinic acetylcholine receptors, 887
- β -Bungarotoxin, B subunit, potassium channel blockade, 164
- Butyric acid, -induced K-562 cells, 3'-azido-3'-deoxythymidine, globin gene transcription (human), 797

C

- Caffeine, inhibition, forskolin-stimulated cyclic AMP, adenosine (rat), 652
- Calcium
- aorta contraction, α_1 -adrenoceptor subtypes (rabbit), 725
 - bradykinin-induced modulation of signals, dorsal root ganglion neurons (rat), 785
 - cGMP and, regulation of cAMP metabolism, parotid gland (mouse), 547
 - dependent and calmodulin-dependent enzymes, inhibition, drug-calmodulin adducts, 698
 - glycine site-directed agonists, reversal of ethanol, NMDA receptor, 753
 - hormone-induced biosynthesis, EDRF/nitric oxide-like material, neuroblastoma cells, 7
 - intracellular distribution, perturbations in kidney cells, haloalkenyl cysteine *S*-conjugates, 455
 - mitochondrial antagonist binding sites, inner mitochondrial membrane anion channel, 362
 - mobilization, cyclic AMP inhibition of polyphosphate production, neuroblastoma x glioma cells, 282
 - mode of action of α -latrotoxin, 917
 - Na⁺-Ca²⁺ exchange activity, central nerve endings (rat), 385, 393
- Calcium channel
- functional coupling, presynaptic GABA_B receptors (mouse), 342
 - inhibition of neuronal currents, funnel web spider toxin ω -Aga-IA, 711
 - interactions with methylmercury, synaptosomes, pheochromocytoma cells, 102
- Calcium current
- L-type, high affinity forskolin inhibition, cardiac cells, 758
 - regulation by low-*K_m* cyclic AMP phosphodiesterases, cardiac cells (frog), 426
 - voltage-activated, inhibition by nordihydroguaiaretic acid, 524
- Calmodulin
- anticalmodulin drugs, dissimilar mechanisms of action, 910
 - dependent enzymes, differential inhibition, drug-calmodulin adducts, 698
 - hormone-induced biosynthesis, EDRF/nitric oxide-like material, neuroblastoma cells, 7
- Camptothecin, -resistant subline of P388 leukemia, reduced topoisomerase I content, 471
- Cannabidiol, inactivation of liver cytochrome P-450III_A (mouse), 319
- Cannabinoid, activity, role of phenolic hydroxyl, 854
- Carbamoylcholine, -stimulated neuroblastoma cells, polyphosphoinositides, major source of inositol phosphates, 54
- Carboxyl terminal, domains, ligand binding, chimeric m2/m3 muscarinic receptors, 872
- Cardiomyocytes, regulation of calcium current, cyclic AMP phosphodiesterases (frog), 426
- Cardiotoxicity, palytoxin (chick), 904
- Catecholamines
- inactivation of tyrosine hydroxylase, pterin substrates, cAMP-dependent protein kinase, 541
 - stimulated adenylyl cyclase, phorbol ester-induced inhibition, β -adrenergic receptor (mouse), 289
- CCRF-CEM cells, inhibition of ribonucleotide reduction, 2',2'-difluorodeoxycytidine, 567

- Cerebellum, rat, inositol 1,4,5-trisphosphate receptors, bovine adrenal cortex, 841
- Chlorethylclonidine, aorta contraction, α_1 -adrenoceptor subtypes (rabbit), 725
- (2-Chloroethyl)-3-sarcosinamide-1-nitrosourea, mechanisms of resistance, glioma cells (human), 299
- Cholecystokinin, cyclic analogues, central cholecystokinin receptors (rat, guinea pig), 333
- Cholestasis, sinusoidal and biliary glutathione release, vasopressin, epinephrine, 64
- C3H/10T $\frac{1}{2}$ cells, increased homocysteine export by cysteamine, glutathione content (mouse), 327
- Cirrhosis, alcoholic, cross-reactivity of antibodies, acetaldehyde adducts, 587
- Computers, quantitative molecular analysis, 5-hydroxytryptamine, receptor binding affinity, 511
- Corpus striatum, influence of pH, scopolamine and *N*-methylscopolamine binding, muscarinic receptors (rat), 143
- Cyclic AMP
- adenosine A₁ receptors, smooth muscle cells, 660
 - calcium and, regulation of cAMP metabolism, parotid gland (mouse), 547
 - dependent protein kinase, inactivation of tyrosine hydroxylase, pterin substrates, 541
 - forskolin-stimulated accumulation, adenosine, caffeine (rat), 652
 - inhibition of polyphosphate production, calcium mobilization, neuroblastoma x glioma cells, 282
 - inhibition of procoagulant activity, pentoxifylline inhibition, activated mononuclear phagocytes, 562
 - phosphodiesterases, regulation of calcium current, cardiac cells (frog), 426
 - phosphorylation-independent effects, second messenger modulators, GABA_A receptor complex function, 823
 - regulation of metabolism, mouse parotid gland, cGMP and calcium (mouse), 547
- Cysteamine, increased homocysteine export, glutathione content, C3H/10T $\frac{1}{2}$ cells (mouse), 327
- Cysteine *S*-conjugates, haloalkenyl, perturbations, intracellular calcium distribution, 455
- Cytochrome CYP2B1, CYP2B2, CYP2C6, CYP3A1 and, localization, phenobarbital-inducible hepatic mRNAs (rat), 462
- Cytochrome P-450
- liver microsomal, cDNA coding, polychlorinated biphenyl treatment (dog), 644
 - reconstitution of LM2-dependent activities, dual role, phospholipid, 134
- Cytochrome P450b/e, P450p mRNAs and, differentiated induction by phenobarbital, hepatocytes (rat), 440
- Cytochrome P-450IIA1, homologue immunochemical analysis, lung microsomes (human), 634
- Cytochrome P-450IIC, subfamily, growth hormone regulation (rat), 192
- Cytochrome P-450IIIA, inactivation, cannabidiol, liver (mouse), 319
- Cytochrome P450IIIA2, male-specific, down-regulation by interferon, liver (rat), 313
- Cytochrome P450IIIA5, expression and metabolic capabilities, 207
- Cytochrome P-450 monooxygenases, flavin-containing, stereoselective *S*-oxygenation, 2-aryl-1,3-dithiolanes, 573

D

- 2'-Deoxy-3'-adenosine monophosphate, tissue levels of 3'-AMP, intracellular inhibitor, adenylyl cyclases, 848
- 2'-Deoxyuridine analogs, cellular metabolism of 3'-azido-2',3'-dideoxyuridine, 2'-deoxyuridine analogs, 929
- Diabetes, tissue levels of 3'-AMP, intracellular inhibitor, adenylyl cyclases, 848
- 5,7-Dichlorokynurenic acid, potent glycine antagonist, 554
- 2'-3'-Dideoxycytidine, toxicity in human CEM T lymphoblasts, 237

- 2',2'-Difluorodeoxycytidine, inhibition of ribonucleotide reduction, CCRF-CEM cells, 567
- Difluoromethylornithine, prevention of down-regulation, type I interferon receptors, 451
- Dihydropyridine, interactions of methylmercury, Ca^{2+} channels, synaptosomes and pheochromocytoma cells, 102
- Dihydroxyaporphines, enantiomeric, presynaptic dopamine inhibition, striatal tissue (rat), 92
- Dilauroylphosphatidylcholine, dual role of phospholipid, reconstitution, cytochrome P-450 LM2-dependent activities, 134
- 5'-*O*-Diphosphohexose, derivatives, cellular metabolism, 3'-azido-2', 3'-dideoxyuridine, 929
- Disulfides, avoidance of dimerization, loss of inhibitory activity, peptide pGlu-Asp-Cys-Lys, 401
- DNA**
- decreased levels of 5-fluorouracil, resistance to 5-FU, ovarian cancer line, 410
 - enzyme cross-inhibition, allosteric interaction, replitase complex (hamster), 114
 - mechanisms of resistance, (2-chloroethyl)-3-sarcosinamide-1-nitroso-urea, human glioma cells, 299
- DNA, complementary, coding for liver microsomal cytochrome P-450, polychlorinated biphenyl treatment (dog), 644
- DNA adducts**
- acetaldehyde, cross-reactivity of antibodies, alcoholic cirrhosis, 587
 - drug-calmodulin adducts, calcium-dependent and calmodulin-dependent enzymes, 698
- DNA topoisomerase I, reduced content, camptothecin-resistant subline, P388 leukemia, 471
- DNA topoisomerases I and II, mammalian, morpholinyl doxorubicins, doxorubicin and Actinomycin D, 38
- Dopamine**
- presynaptic inhibition, enantiomeric mono- and dihydroxyaporphines, striatal tissue (rat), 92
 - release, Na^+ - Ca^{2+} exchange activity, central nerve endings (rat), 393
- Dorsal root ganglion, neurons, bradykinin-induced modulation, calcium signals (rat), 785
- Doxorubicin, morpholinyl doxorubicins and Actinomycin D, mammalian DNA topoisomerases I and II, 38
- DuP 753, subclasses, angiotensin II binding sites, functional significance, 370
- E**
- Electrolytes, ileal transport, regulation, M_3 -muscarinic acetylcholine receptors (guinea pig), 836
- Endothelin, internalization, human vascular smooth muscle cells, 244
- Endothelium, aortic, purinergic P_2 receptors, 84
- Endothelium-derived relaxing factor, nitric oxide-like material, hormone-induced biosynthesis, neuroblastoma cells, 7
- Enterocytes, regulation of ileal electrolyte transport, M_3 -muscarinic acetylcholine receptors (guinea pig), 836
- Epidermal growth factor, stimulation of linoleic acid metabolism, BALB/c 3T3 fibroblasts, 503
- Epilepsy, quantitative evaluation of benzodiazepine receptors, positron emission tomography (baboon), 445
- Epinephrine, sinusoidal and biliary release of glutathione, cholestasis, 64
- Estrogen, -responsive breast cancer cells, proliferation, hydroxylated metabolites of tamoxifen, 737
- Ethanol**
- in vivo* formation of free radical metabolite (deermouse), 26
 - oxygen uptake and toxicity, menadione bisulfite, liver (rat), 959
 - reversal of actions, glycine-directed agonists, NMDA receptor, 753
- F**
- Fibroblasts, BALB/c 3T3, linoleic acid metabolism, epidermal growth factor, 503
- Flavin, -containing and cytochrome P-450 monooxygenases, stereoselective *S*-oxygenation, 2-aryl-1,3-dithiolanes, 573
- Flunitrazepam, photoaffinity labeling, liver microsomal morphine UDP-glucuronosyltransferase (rat), 294
- 5-Fluorouracil, resistance of ovarian cancer line, decreased levels of 5-FU in DNA, 410
- FMLP, arachidonic acid release mechanism, alveolar macrophages (guinea pig), 418
- Forebrain**
- binding of selective antagonists, muscarinic receptors (rat), 267
 - homomeric GluR1 excitatory amino acid receptors, *Xenopus* oocytes, 779
- Forskolin**
- high infinity inhibition, L-type Ca^{2+} current, cardiac cells, 758
 - stimulated cyclic AMP accumulation, adenosine, caffeine (rat), 652
- G**
- Genes**
- growth hormone regulation, cytochrome P-450IIC subfamily (rat), 192
 - jun*-B, regulation by 1- β -D-arabinofuranosylcytosine, myeloid leukemia cells (human), 435
 - transcriptional program coordination, NMDA glutamate receptor, cerebellar neurons (rat), 624
- Glioma**
- mechanisms of resistance, (2-chloroethyl)-3-sarcosinamide-1-nitroso-urea (human), 299
 - neuroblastoma hybrid, cyclic AMP inhibition, polyphosphate production and calcium mobilization, 282
- Globin, gene transcription inhibition, 3'-azido-3'-deoxythymidine, butyric acid-induced K-562 cells (human), 797
- Glucuronidation, hepatic monooxygenation and, regulation, unique role of oxygen, 128
- Glutathione**
- inactivation of tyrosine hydroxylase, pterin substrates, cAMP-dependent protein kinase, 541
 - increased homocysteine export by cysteamine, C3H/10T $\frac{1}{2}$ cells (mouse), 327
 - sinusoidal and biliary release, cholestasis, vasopressin and epinephrine, 64
 - stimulation of porphyrinogen oxidation, mercuric ion, 261
- Glycine**
- antagonist, 5,7-dichlorokynurenic acid, 554
 - noncompetitive antagonism of binding, zinc, NMDA receptor-gated ion channel, 14
 - site-directed agonists, reversal of ethanol actions, NMDA receptor, 753
- Glycoproteins, A_2 -adenosine receptor binding subunit, 177
- G-proteins**
- activation of G_i -like proteins, receptor-independent effect of kinins, mast cells (rat), 816
 - analysis of agonist-antagonist interactions, adenosine A_1 receptors, 72
- Growth hormone, regulation of cytochrome P-450IIC subfamily (rat), 192
- GTP-binding protein**
- adenosine A_1 receptors, smooth muscle cells, 660
 - arachidonic acid release mechanism, FMLP, alveolar macrophages (guinea pig), 418
 - 1-(4-bromo-2,5-dimethoxy)-4-bromoamphetamine and ketanserin, labeling of affinity sites, 5-HT $_2$ receptor, 604
 - cloning and pharmacological characterization, human α_{2B} -adrenergic receptor, 681
 - coupling between inhibitory receptors, sulfhydryl-modifying reagents, 3-nitro-2-pyridinesulfonyl compounds (rat), 184
- Guanine nucleotide-binding proteins**
- A_1 -adenosine receptors, platelet membranes, 170
 - delineation of muscarinic receptor domains, coupling selectivity, second messengers, 517

Guanosine triphosphate, signaling through muscarinic receptor-adenylate cyclase system, heart (rat), 148

H

Heart

- high affinity forskolin inhibition, L-type Ca^{2+} currents, 758
- influence of pH, scopolamine and *N*-methylscopolamine binding, muscarinic receptors (rat), 143
- mechanism of cardiotoxin action (chick), 904
- muscarinic M_4 binding sites, NG108-15 cells (rabbit, chicken), 815
- regulation of calcium current, cyclic AMP phosphodiesterases (frog), 426
- signaling, muscarinic receptor-adenylate cyclase system (rat), 148
- Heme, age-related change in pattern of expression, biliverdin reductase, liver and brain (rat), 481
- Hemin, phenobarbitone-inducible enzymes, levels of hepatic mRNAs (rat), 486
- Hemopoiesis, avoidance of dimerization, loss of inhibitory activity, peptide pGlu-Asp-Cys-Lys, 401
- Hepatocytes, differentiated induction, cytochrome P450b/e and P450p mRNAs, phenobarbital (rat), 440
- Hepatotoxicity, *in vivo* formation, free radical metabolite, ethanol (deermouse), 26
- HIV-1, inhibition of reverse transcriptase activity, rubromycins, 20
- Homocysteine, increased export by homocysteine, glutathione content, C3H/10T $\frac{1}{2}$ cells (mouse), 327
- Human immunodeficiency virus, reverse transcriptase, reversal, ribavirin, 766
- Hydrogen peroxide
 - mitochondria-generated, porphyrinogen oxidation, mercuric ion, 261
 - stimulation of porphyrinogen oxidation, mercuric ion, 253
- 5-Hydroxytryptamine $_2$, receptor binding affinity, prediction, quantitative molecular analysis, 511
- Hydroxyurea, enzyme cross-inhibition, allosteric interaction, replitase complex (Chinese hamster), 114
- Hypotension, platelet-activating factor receptor antagonist, biological effect, SM-10661, 378

I

Ileum

- electrolyte transport, regulation, M_3 -muscarinic acetylcholine receptors (guinea pig), 836
- longitudinal muscle, muscarinic receptor subtypes, adenylyl cyclase (rat), 689
- Inositol 1,4,5-trisphosphate, partial characterization of receptor, bovine adrenal cortex, rat cerebellum, 841
- Inositol phosphate
 - comparison of P_2 purinergic receptors, aortic endothelium adrenal medulla, 84
 - norepinephrine-stimulated, pertussis toxin inhibition, primary brain cell cultures (rat), 274
 - polyphosphoinositides as major source, carbamoylcholine-stimulated neuroblastoma cells, 54
- Inositol phospholipids, internalization of endothelin, human vascular smooth muscle cells, 244
- Interferon
 - down-regulation, male-specific cytochrome P450III λ 2, liver (rat), 313
 - type I, prevention of down-regulation, difluoromethylornithine, 451
- Iodoclonidine
 - novel radiolabeled agonist, central α_2 -adrenergic receptors, 348
 - partial agonist at α_2 -adrenergic receptor, 214
- 4-[^{125}I]iodo-(2,5-dimethoxy)phenylisopropylamine, labeling of transfected cells, 5-HT $_2$ receptors, 594
- Ion channels
 - NMDA receptor-gated, zinc, antagonism of glycine binding, 14
 - thymopoietin interactions, nicotinic acetylcholine receptors, α -bungarotoxin binding sites, 887

Ischemia-reperfusion injury, hepatic mixed function oxidase system (rat), 829

K

- K-562 cells, butyric acid-induced, 3'-azido-3'-deoxythymidine, globin gene transcription inhibition (human), 797
- Ketanserin
 - 1-(4-bromo-2,5-dimethoxy)-4-bromoamphetamine and, affinity sites, cloned human 5-HT $_2$ receptor, 604
 - labeling of transfected cells, 5-HT $_2$ receptors, 594
- KHL-8430, anticalmodulin drugs, dissimilar mechanisms of action, 910
- Kidney, perturbations of intercellular calcium distribution, nephrotoxic haloalkenyl cysteine *S*-conjugates, 455
- Kinins, receptor-independent effect, activation of G_i -like proteins, mast cells (rat), 816

L

- α -Latrotoxin, mode of action, 917
- Leukemia, myeloid, regulation of *jun*-B gene expression, 1- β -D-arabinofuranosylcytosine (human), 435
- Leukemia, P388, stable camptothecin-resistant subline, reduced topoisomerase I content, 471
- Ligands, quantitative evaluation of benzodiazepine receptors, positron emission tomography (baboon), 445
- Lipoxygenase, linoleic acid metabolism, epidermal growth factor, BALB/c 3T3 fibroblasts, 503
- Liver
 - age-related change in pattern of expression, biliverdin reductase (rat), 481
 - cytochrome P450III λ 5, expression and metabolic capabilities, 207
 - growth hormone regulation, cytochrome P-450IIC subfamily (rat), 192
 - hepatic monooxygenation and glucuronidation, regulation, unique role of oxygen, 128
 - inactivation of cytochrome P-450III λ , cannabidiol (mouse), 319
 - male-specific cytochrome P450III λ 2, down-regulation by interferon (rat), 313
 - microsomal cytochrome P-450, cDNA coding, polychlorinated biphenyl treatment (dog), 644
 - microsomal morphine UDP-glucuronosyltransferase, photoaffinity labeling by flunitrazepam (rat), 294
 - mixed function oxidase system, ischemia-reperfusion injury (rat), 829
 - oxygen uptake and toxicity, ethanol potentiation, menadione bisulfite (rat), 959
 - phenobarbital-inducible hepatic mRNAs, CYP2B1/CYP2B2/CYP2C6/CYP3A1 (rat), 462
 - sinusoidal and biliary release of glutathione, cholestasis, vasopressin and epinephrine, 64
 - tissue levels of 3'-AMP, intracellular inhibitor, adenylyl cyclases, 848
- Lung
 - microsomes, immunochemical analysis, cytochrome P-450IA1 (human), 634
 - muscarinic M_4 binding sites, NG108-15 cells (rabbit, chicken), 815
- LY53857, contractile response to serotonin, 5-HT $_{1C}$ receptors, stomach fundus (rat), 31
- Lymphoblasts, 2',3'-dideoxycytidine toxicity, 237

M

- Macrophages, alveolar, arachidonic acid release, FMLP (guinea pig), 418
- Magnesium, -induced *N*-(1-[thienyl]cyclohexyl)piperidine binding, arcaïne, competitive inhibition (rat), 705
- Mast cells, activation of G_i -like proteins, receptor-independent effect, kinins (rat), 816

- McN-A-343, selectivity, phosphoinositide hydrolysis, M₁-muscarinic receptors, 895
- Melanoma, B16, prevention of down-regulation, type I interferon receptors, difluoromethylornithine, 451
- Menadione bisulfite, oxygen uptake and toxicity, menadione bisulfite, liver (rat), 959
- Mercuric ion, stimulation of porphyrinogen oxidation, 253, 261
- Methylmercury, interactions with Ca²⁺ channels, synaptosomes, pheochromocytoma cells, 102
- N*-Methylscopolamine
alcuronium and, binding to muscarinic acetylcholine receptors (rat), 674
binding to muscarinic receptors, pH influence, corpus striatum and heart (rat), 143
- 5-Methyl-urapidil, aorta contraction, α_1 -adrenoceptor subtypes (rabbit), 725
- Microsomes
lung, immunochemical analysis, cytochrome P-450IA1 (human), 634
morphine UDP-glucuronosyltransferase, photoaffinity labeling by flunitrazepam, liver (rat), 294
- Mitochondria
-generated hydrogen peroxide, porphyrinogen oxidation, mercuric ion, 261
inner membrane anion channel, Ca²⁺ antagonist binding sites, 362
- Mixed function oxidase system, hepatic ischemia-reperfusion injury (rat), 829
- Monocytes, neutrophils and, peroxidase-dependent oxidation, sulfonamides (human, dog), 744
- Monohydroxyaporphines, enantiomeric, presynaptic dopamine inhibition, striatal tissue (rat), 92
- Morphine, UDP-glucuronosyltransferase, photoaffinity labeling by flunitrazepam, liver (rat), 294
- Morpholinyl doxorubicins, doxorubicin and Actinomycin D, mammalian DNA topoisomerases I and II, 38
- Multidrug resistance, phenotype, auromycin-resistant hamster cell mutants, 198
- Muscle, smooth
adenosine A₁ receptors, 660
longitudinal muscle of ileum, muscarinic receptor subtypes, adenylate cyclase (rat), 689
pregnant myometrium, voltage-sensitive sodium channels (rat), 667
vascular, internalization of endothelin, 244
- Myometrium, pregnant, smooth muscle cells, voltage-sensitive sodium channels (rat), 667

N

- NADPH, unique role of oxygen, regulation, hepatic monooxygenation and glucuronidation, 128
- N1E-115 cells, differentiation, up-regulation of angiotensin II receptors (mouse), 878
- Nerve, central, Na⁺-Ca²⁺ exchange activity (rat), 385, 393
- Neuroblastoma
agonist-induced desensitization, D₁-dopamine receptors, adenylyl cyclase activity, 531
biochemical characterization, cholecystokinin receptor, 159
carbamoylcholine-stimulated, polyphosphoinositides, major source of inositol phosphates, 54
differentiation, up-regulation of angiotensin II receptors (mouse), 878
glioma hybrid, cyclic AMP inhibition, polyphosphate production and calcium mobilization, 282
hormone-induced biosynthesis, EDRF/nitric oxide-like material, 7
- Neuromuscular blockers, alcuronium and *N*-methylscopolamine, binding, muscarinic acetylcholine receptors (rat), 674
- Neurons
cerebellar, transcriptional program coordination, NMDA glutamate receptor (rat), 624
dorsal root ganglion, bradykinin-induced modulation, calcium signals

- (rat), 785
inhibition of neuronal Ca²⁺ channel currents, funnel web spider toxin ω -Aga-IA, 711
neocortical, lack of cross-sensitization, somatostatin-14 and -28 receptors (rat), 357
spinal cord
desensitization, GABA_A receptors (mouse), 719
presynaptic GABA_B receptors, calcium channel (mouse), 342
striatal
GABA release, kainate receptors (mouse), 229
quisqualate phosphoinositide-coupled receptors, (*trans*)-1-amino-cyclopentyl-1,3-dicarboxylate (*Xenopus* oocytes), 1
- Neuropeptide Y
gene expression in adrenal gland, reserpine treatment (rat), 614
vas deferens receptors, brain neuropeptide binding sites (rat), 494
- Neurotransmitter, mode of action of α -lactotoxin, 917
- Neutrophils, monocytes and, peroxidase-dependent oxidation, sulfonamides (human, dog), 744
- NG108-15 cells, muscarinic M₄ binding sites (rabbit, chicken), 815
- Nitric oxide, -like material, hormone-induced biosynthesis, neuroblastoma cells, 7
- 3-Nitro-2-pyridinesulfonyl compounds, sulfhydryl-modifying reagents, coupling between inhibitory receptors, GTP-binding proteins (rat), 184
- Nordihydroguaiaretic acid, inhibition of voltage-activated Ca²⁺ currents, independence, lipoxygenase inhibition, 524
- Norepinephrine, -stimulated inositol phosphate, pertussis toxin inhibition, primary brain cell cultures (rat), 274

O

- Oocytes
Xenopus
homomeric GluR1 excitatory receptors, 779
(*trans*)-1-amino-cyclopentyl-1,3-dicarboxylate, quisqualate phosphoinositide-coupled receptors, 1
- Ovarian cancer, resistance to 5-fluorouracil, decreased levels of 5-FU in DNA, 410
- Oxygen
regulation of monooxygenation, glucuronidation, 128
uptake and toxicity, potentiation by ethanol, menadione bisulfite in liver (rat), 959
- Oxymetazoline, cloning and pharmacological characterization, human α_{2B} -adrenergic receptor, 681

P

- Palytoxin, mechanism of cardiotoxic action (chick), 904
- Parotid gland, regulation of cAMP metabolism, cGMP and calcium (mouse), 547
- Patch-clamp
bradykinin-induced modulation of calcium signals, dorsal root ganglion neurons (rat), 785
L-type Ca²⁺ currents, high affinity forskolin, cardiac cells, 758
voltage-sensitive sodium channels, smooth muscle cells, pregnant myometrium (rat), 667
- PD 123319, subclasses, angiotensin II binding sites, functional significance, 370
- Pentoxyfylline, inhibition of procoagulant activity, activated mononuclear phagocytes, 562
- Peptides, pGlu-Asp-Cys-Lys, synthetic derivative, avoidance of dimerization and loss of inhibitory activity, 401
- Peroxidase, -dependent oxidation of sulfonamides, monocytes and neutrophils (human, dog), 744
- Pertussis toxin
inhibition, norepinephrine-stimulated inositol phosphate, primary brain cell cultures (rat), 274
interaction of guanine nucleotide-binding proteins, brain A₁-adenosine receptors, platelet membranes, 170
3-nitro-2-pyridinesulfonyl compounds, receptors and G proteins, brain membranes (rat), 184

- pH, binding of scopolamine and *N*-methyloscopolamine, muscarinic receptors, corpus striatum and heart (rat), 143
- Phagocytes, activated mononuclear, pentoxifylline inhibition, procoagulant activity, 562
- Pharmacophore, 5-hydroxytryptamine, receptor binding affinity, prediction, quantitative molecular analysis, 511
- Phenobarbital
differentiated induction, cytochrome P450b/e and P450p mRNAs, hepatocytes (rat), 440
-inducible hepatic mRNAs, localization, cytochromes CYP2B1/CYP2B2/CYP2C6/CYP3A1 (rat), 462
- Phenobarbitone, -inducible enzymes, hemin effect, levels of hepatic mRNAs (rat), 486
- Phenolic hydroxyl, role in cannabinoid activity, 854
- Pheochromocytoma cells, interactions of methylmercury, Ca²⁺ channels, 102
- Phorbol ester, -induced inhibition, catecholamine-stimulated adenylyl cyclase, β -adrenergic receptor (mouse), 289
- Phosphatidylethanolamine, acetaldehyde adducts, cross-reactivity of antibodies, alcoholic cirrhosis, 587
- Phosphoinositide
-coupled excitatory amino acid receptors, stereoselectivity, 2-amino-3-phosphonopropionic acid (rat), 222
hydrolysis
McN-A-343 selectivity, M₁-muscarinic receptors, 895
muscarinic receptor subtypes, ileum longitudinal muscle (rat), 689
- Phosphoinositide hydrolysis, chimeric m2/m3 muscarinic receptors, carboxyl terminal receptor domains, 872
- Phospholipids, reconstitution of cytochrome P-450, LM2-dependent activities, dual role, 134
- Phosphorylation, -independent effects, second messenger modulators, GABA_A receptor complex function, 823
- Platelet-activating factor
arachidonic acid release mechanism, FMLP, alveolar macrophages (guinea pig), 418
receptor antagonist SM-10661, biological effect, 378
- Platelet membranes, brain A₁-adenosine receptors, interaction with guanine nucleotide-binding proteins, 170
- Platelets, heterologous desensitization of adenylyl cyclase, prostaglandins, 46
- Polychlorinated biphenyl, cDNA coding, liver microsomal cytochrome P-450 (dogs), 644
- Polyphosphate, cyclic AMP inhibition of production, calcium mobilization, neuroblastoma x glioma cells, 282
- Polyphosphoinositides, major source of inositol phosphates, carbamoylcholine-stimulated neuroblastoma cells, 54
- Porphyrinogen, stimulation of oxidation by mercuric ion, 253, 261
- Positron emission tomography, quantitative evaluation, benzodiazepine receptors (baboon), 445
- Potassium channel
blockade by B subunit of β -bungarotoxin, 164
lack of cross-sensitization, somatostatin-14 and -28 receptors, neocortical neurons (rat), 357
- Prazosin, cloning and pharmacological characterization, human α_{2B} -adrenergic receptor, 681
- Pregnancy, myometrium, smooth muscle cells, voltage-sensitive sodium channels (rat), 667
- Prostaglandins, heterologous desensitization, adenylyl cyclase, 46
- Protein, acetaldehyde adducts, cross-reactivity of antibodies, alcoholic cirrhosis, 587
- Protein kinase, cAMP-dependent, inactivation of tyrosine hydroxylase, pterin substrates, 541
- Protein kinases
arachidonic acid release mechanism, FMLP, alveolar macrophages (guinea pig), 418
GABA_A receptor desensitization, spinal cord neurons (mouse), 719
presynaptic GABA_B receptors, functional coupling, calcium channel (mouse), 342
- Pterin, substrates, inactivation of tyrosine hydroxylase, cAMP-dependent protein kinase, 541
- Q**
- Quisqualate phosphoinositide, -coupled receptors, (*trans*)-1-amino-cyclopentyl-1,3-dicarboxylate, striatal neurons and *Xenopus* oocytes, 1
- R**
- Receptors
activation of G_i-like proteins, kinins, mast cells (rat), 816
adenosine A₁
analysis, agonist-antagonist interactions, 72
binding, enhancement by 2-amino-3-benzoylthiophenes, 939, 950
guanine nucleotide-binding proteins, platelet membranes, 170
smooth muscle cells, 660
adenosine A₂, binding subunit, glycoprotein nature, 177
A_h, characterization, strain distribution pattern (mouse), 306
 α _{1A}, α _{1A}-adrenergic receptor subtypes (rat), 599
angiotensin II, up-regulation, differentiation of neuroblastoma cells (mouse), 878
benzodiazepine, quantitative evaluation, positron emission tomography (baboon), 445
cholecystokinin
biochemical characterization, neuroblastoma cells, 159
cyclic cholecystokinin analogues (rat, guinea pig), 333
dopamine D₁, agonist-induced desensitization, adenylyl cyclase activity in neuroblastoma cells, 531
excitatory amino acid, stereoselectivity, 2-amino-3-phosphonopropionic acid (rat), 222
GABA_A
desensitization, spinal cord neurons (mouse), 719
second messenger system modulators, phosphorylation-independent effects, 823
histamine H₃ subtypes (rats), 610
homomeric GluR1 excitatory, *Xenopus* oocytes, 779
5-HT_{1A}, characterization, human α_{2B} -adrenergic receptor, 681
5-HT_{1C}, contractile response to serotonin, stomach fundus (rat), 31
5-HT₂
affinity sites, 1-(4-bromo-2,5-dimethoxy)-2-bromoamphetamine and ketanserin, 604
4-[¹²⁵I]iodo-(2,5-dimethoxy)phenylisopropylamine and [³H]ketanserin labeling, transfected cells, 594
5-HT₃, quantitative molecular binding, 511
inhibitory, 3-nitro-2-pyridinesulfonyl compounds, G proteins (rat), 184
inositol 1,4,5-trisphosphate, bovine adrenal cortex, rat cerebellum, 841
interferon type I, prevention of down-regulation, difluoromethylornithine, 451
kainate, GABA release, striatal neurons (mouse), 229
N-methyl-D-aspartate, zinc, antagonism of glycine binding, 14
muscarinic
adenylyl cyclase signaling, heart (rat), 148
binding of selective antagonists, forebrain (rat), 267
coupling mechanisms in smooth muscle (rat), 689
delineation of domains, coupling selectivity, 517
scopolamine and *N*-methyloscopolamine binding, pH influence (rat), 143
muscarinic acetylcholine, binding, alcuronium and *N*-methyloscopolamine (rat), 674
muscarinic chimeric m2/m3, carboxyl terminal domains, ligand binding, 872
muscarinic M₁, McN-A-343 selectivity, phosphoinositide hydrolysis, 895
muscarinic M₃, regulation, ileal electrolyte transport (guinea pig), 836

- muscarinic M₄, binding sites, lung, heart, and NG108-15 cells (rabbit, chicken), 815
- neuropeptide Y, vas deferens, brain neuropeptide binding sites (rat), 494
- nicotinic acetylcholine
- thymopentin effects, cholinergic agonist-induced slow activation (*Torpedo californica*, *Xenopus*), 863
 - thymopointin interactions, α -bungarotoxin binding sites, 887
- NMDA, glycine site-directed agonists, reversal of ethanol actions, 753
- NMDA glutamate, transcriptional program coordination, cerebellar neurons (rat), 624
- δ -opioid, selective cyclic dermorphin-like tetrapeptides, 924
- presynaptic GABA_B, functional coupling, voltage-gated Ca²⁺ channel (mouse), 342
- purinergic P₂, aortic endothelium, adrenal medulla, 84
- quisqualate phosphoinositide-coupled, (*trans*)-1-amino-cyclopentyl-1,3-dicarboxylate, striatal neurons and *Xenopus* oocytes, 1
- stimulatory and inhibitory, heterologous desensitization, adenylate cyclase, 46
- Replisase complex, allosteric interaction, enzyme cross-inhibition (hamster), 114
- Reserpine, neuropeptide Y gene expression, adrenal gland (rat), 614
- Ribavirin, inhibitor of HIV reverse transcriptase, 766
- Ribonucleotide, inhibition of reduction in CCRF-CEM cells, 2',2'-difluorodeoxycytidine, 567
- Ritanserin, contractile response to serotonin, 5-HT_{1C} receptors, stomach fundus (rat), 31
- RNA, messenger
- hepatic, hemin effect, phenobarbitone-inducible enzymes (rat), 486
 - homomeric GluR1 excitatory amino acid receptors, *Xenopus* oocytes, 779
 - phenobarbital-inducible hepatic, localization, cytochromes CYP2B1/CYP2B2/CYP2C6/CYP3A1 (rat), 462
 - three α_2 -adrenergic receptor subtypes, tissues (rat), 599
- Rubromycins, inhibition, HIV-1 reverse transcriptase activity, 20

S

- SCH 23390, contractile response to serotonin, 5-HT_{1C} receptors, stomach fundus (rat), 31
- Scopolamine, binding to muscarinic receptors, pH influence, corpus striatum and heart (rat), 143
- Serotonin
- contractile response, 5-HT_{1C} receptor, stomach fundus (rat), 31
 - 5-hydroxytryptamine, receptor binding affinity, prediction, quantitative molecular analysis, 511
- SM-10661, platelet-activating factor receptor antagonist, biological effect, 378
- Sodium, Na⁺-Ca⁺ exchange activity, central nerve endings (rat), 385, 393
- Sodium channels, voltage-sensitive, smooth muscle cells, pregnant myometrium (rat), 667
- Somatostatin-14, somatostatin-28 receptors and, lack of cross-sensitization, neocortical neurons (rat), 357
- Spermidine, -magnesium binding site, Mg-induced N-(1-[thienyl]cyclohexyl)piperidine binding, arcaine (rat), 705
- Spinal cord
- neurons
 - desensitization, GABA_A receptors (mouse), 719
 - presynaptic GABA_B receptors, calcium channel (mouse), 342
- Stem cells, avoidance of dimerization, loss of inhibitory activity, peptide pGlu-Asp-Cys-Lys, 401

- Stomach fundus, contractile response to serotonin, 5-HT_{1C} receptor (rat), 31
- Striatum, presynaptic dopamine inhibition, enantiomeric mono- and dihydroxyaporphines (rat), 92
- Sulfonamides, peroxidase-dependent oxidation, monocytes and neutrophils (human, dog), 744
- Sulhydryl-modifying reagents, 3-nitro-2-pyridinesulfonyl compounds, receptors and G proteins, brain membranes (rat), 184
- Synaptosomes
- interactions of methylmercury, Ca²⁺ channels, 102
 - potassium channel blockade, B subunit of β -bungarotoxin, 164

T

- Tamoxifen, hydroxylated metabolites, proliferation, estrogen-responsive breast cancer cells, 737
- Tetrapeptides, cyclic dermorphin-like, δ -opioid receptor selectivity, 924
- Thiols, stimulation of porphyrinogen oxidation, mercuric ion, 253
- Thiopramide, identification of H₃-histamine receptor subtypes (rat), 610
- Thymidylate synthase, enzyme cross-inhibition, allosteric interaction, replisase complex (hamster), 114
- Thymopentin, cholinergic agonist-induced slow activation, nicotinic receptor function, 863
- Thymopointin, interactions with neuronal nicotinic α -bungarotoxin binding sites, muscle-type nicotinic acetylcholine receptor ligand-gated ion channels, 887
- Torpedo californica*, cholinergic agonist-induced slow activation, thymopentin effects, nicotinic acetylcholine receptor function, 863
- Transglutaminase, internalization of endothelin, human vascular smooth muscle cells, 244
- Tyrosine hydroxylase
- inactivation by pterin substrates, phosphorylation, cyclic AMP-dependent protein kinase, 541
 - presynaptic dopamine inhibition, enantiomeric mono- and dihydroxyaporphines, striatal tissue (rat), 92

U

- U-937 cells, inhibition of procoagulant activity, pentoxifylline inhibition, activated mononuclear phagocytes, 562
- UDP-glucuronosyltransferase, microsomal morphine, photoaffinity labeling by flunitrazepam, liver (rat), 294

V

- Vas deferens, neuropeptide Y receptors, brain neuropeptide binding sites (rat), 494
- Vasopressin, sinusoidal and biliary release of glutathione, cholestasis, 64

X

- Xenopus*
- cholinergic agonist-induced slow activation, thymopentin effects, nicotinic acetylcholine receptor function, 863
 - oocytes, homomeric GluR1 excitatory receptors, 779

Y

- Yohimbine, cloning and pharmacological characterization, human α_{2B} -adrenergic receptor, 681

Z

- Zinc, inhibition of NMDA receptor-gated ion channel activation, non-competitive antagonism, glycine binding, 14

**Copyright © 1990 by the American Society for
Pharmacology and Experimental Therapeutics**

Previous Editors

- 1965** Avram Goldstein, *Editor*. Stanford University.
1968 Paul Talalay, *Editor*; Donald S. Coffey, *Associate Editor*. Johns Hopkins University.
1971 Steven E. Mayer, *Editor*, Palmer W. Taylor, *Associate Editor*. University of California at San Diego.
1975 George I. Drummond, *Editor*; H. Joseph Goren, *Associate Editor*. University of Calgary.
1978 Norman Kirschner, *Editor*; Theodore A. Slotkin, *Associate Editor*. Duke University.
1983 Joel G. Hardman, *Editor*; Lee Limbird, F. Peter Guengerich, *Associate Editors*. Vanderbilt University.

INFORMATION TO SUBSCRIBERS

MOLECULAR PHARMACOLOGY is published monthly, two volumes a year, beginning in January & July. Instructions to Authors will be found in every issue.

Correspondence concerning business matters should be addressed to Williams & Wilkins, 428 East Preston St., Baltimore, Maryland 21202-3993 U.S.A.

Correspondence regarding editorial matters should be addressed to the Editor, Dr. William A. Catterall, Department of Pharmacology, SJ-30, University of Washington, Seattle, WA 98195.

Annual Subscription Rates—U. S. A. AND POSSESSIONS: personal, \$90.00; institutional, \$195.00, single copy, \$17.00. FOREIGN: personal, \$120.00; institutional, \$225.00; single copy, \$20.00. (Prices subject to change.) Institutional (multiple reader) rate applies to libraries, schools, hospitals, clinics, group practices, and federal, commercial, and private institutions and organizations. Foreign subscribers who wish to have issues sent by air mail may inquire of the publisher for the additional cost.

Change of address: Publisher must be notified 60 days in advance. Journals undeliverable because of incorrect address will be destroyed. Duplicates can be obtained (if available) from the publisher at the regular price of single issues.

New subscriptions and renewals are entered to begin with the January or July issue.

To avoid a break in your series, subscriptions should be renewed promptly. The publisher cannot guarantee to supply back issues on belated renewals.

Reprints of individual articles are available *only* from authors.

Microfilm. For availability, inquire of Williams & Wilkins.

Williams & Wilkins, Baltimore, MD. 21202-3993 U. S. A.